Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WD8M
|
|||
| Former ID |
DAP001362
|
|||
| Drug Name |
Connexyn
|
|||
| Synonyms |
Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10Cl3N3O
|
|||
| Canonical SMILES |
C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl
|
|||
| InChI |
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
|
|||
| InChIKey |
DGFYECXYGUIODH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 29110-48-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7847672, 10321692, 11532959, 12013435, 14799743, 17405082, 43127732, 49878427, 50106306, 50125709, 53777625, 56422899, 57318182, 75139922, 85273773, 91011797, 92125343, 92304014, 103770477, 103840710, 103914179, 104350375, 117464967, 124891653, 126657731, 131315423, 134338574, 135030202, 137074791, 144075859, 144203710, 152106277, 160838238, 162174779, 162247844, 163098785, 163135011, 163403921, 163564473, 163621092, 163686415, 164814341, 170465381, 172908369, 175266064, 175611116, 175611812, 179149181, 185983130, 196106983
|
|||
| ChEBI ID |
CHEBI:5559
|
|||
| ADReCS Drug ID | BADD_D01047 | |||
| SuperDrug ATC ID |
C02AC02
|
|||
| SuperDrug CAS ID |
cas=029110472
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Agonist | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents, 2009. FDA Approved - September 2, 2009 | |||
| REF 2 | alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.